MHDC Pharmaceutical Co.

MHDC specializes in the R&D and commercialization of innovative pharmaceutical formulations products. The founding team possesses extensive knowledge and experience in global advanced formulation technologies and cGMP quality. Since its establishment, MHDC has secured capital investment and support from listed companies and industry funds. The company completed its Round C financing in July 2024, with a cumulative investment of approximately $43 million . MHDC's core business has expanded to include the R&D and commercialization of several major categories: long-acting injectable microsphere formulations, and other complex formulations. Its product portfolio comprises over 20 varieties, including semaglutide long-acting microspheres and other products.